Humana Inc. $HUM Shares Purchased by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC has increased its holdings in Humana Inc. by 33.4%, now owning 14,453 shares worth approximately $3.53 million.
• Humana reported quarterly earnings of $6.27 EPS, slightly missing analysts' estimates of $6.32, but revenue increased by 9.6% year-over-year.
• The company has declared a $0.885 quarterly dividend, translating to an annualized payout of $3.54 and a yield of 1.4%.

Vanguard Personalized Indexing Management LLC increased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 33.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,453 shares of the insurance provider's stock after buying an additional 3,616 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Humana were worth $3,534,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC increased its holdings in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the period. Garde Capital Inc. acquired a new position in Humana in the 1st quarter worth approximately $36,000. Zions Bancorporation National Association UT acquired a new position in Humana in the 1st quarter worth approximately $37,000. Ransom Advisory Ltd acquired a new position in Humana in the 1st quarter worth approximately $66,000. Finally, Rakuten Securities Inc. increased its holdings in Humana by 50.0% in the 1st quarter. Rakuten Securities Inc. now owns 300 shares of the insurance provider's stock worth $79,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

Humana stock opened at $261.19 on Wednesday. The company's fifty day moving average price is $280.05 and its 200 day moving average price is $258.11. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35. The stock has a market capitalization of $31.41 billion, a P/E ratio of 20.05, a P/E/G ratio of 1.59 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same period in the prior year, the business posted $6.96 EPS. Humana's revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. Humana's dividend payout ratio (DPR) is currently 27.17%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada increased their price target on shares of Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Guggenheim reaffirmed a "buy" rating on shares of Humana in a research note on Friday, October 3rd. Evercore ISI started coverage on shares of Humana in a research note on Monday, September 22nd. They set an "in-line" rating and a $295.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Humana in a research note on Wednesday, October 8th. Finally, Piper Sandler dropped their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Humana presently has a consensus rating of "Hold" and an average price target of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.